{"id":28313,"date":"2021-11-04T14:30:12","date_gmt":"2021-11-04T14:30:12","guid":{"rendered":"https:\/\/breastcancer.knowledgehub.wiley.com\/artikel\/"},"modified":"2024-03-14T09:14:19","modified_gmt":"2024-03-14T09:14:19","slug":"artikel","status":"publish","type":"page","link":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/","title":{"rendered":"Artikel"},"content":{"rendered":"\n<h1>\n\t\tArtikel &#8211; Brustkrebs\n\t<\/h1>\n\t<p>Eine speziell zusammengestellte Liste von Artikeln mit Peer-Review, in denen die neuesten Fortschritte bei der Diagnose und Behandlung von Patientinnen mit Brustkrebs im Fr\u00fchstadium oder metastasiertem Brustkrebs behandelt werden.<\/p>\n<select><option data-filter=\"*\" value=\"all\">Filtern nach Thema<\/option><option data-filter=\".uabb-masonary-cat-136\">Abemaciclib<\/option><option data-filter=\".uabb-masonary-cat-137\">Adjuvante Therapie<\/option><option data-filter=\".uabb-masonary-cat-138\">Anastrozol<\/option><option data-filter=\".uabb-masonary-cat-144\">Brustkrebs im Fr\u00fchstadium<\/option><option data-filter=\".uabb-masonary-cat-139\">CDK4\/6<\/option><option data-filter=\".uabb-masonary-cat-140\">Chemotherapie<\/option><option data-filter=\".uabb-masonary-cat-143\">Dalpiciclib<\/option><option data-filter=\".uabb-masonary-cat-145\">Endokrine Therapie<\/option><option data-filter=\".uabb-masonary-cat-141\">Klinische Studien<\/option><option data-filter=\".uabb-masonary-cat-142\">Konferenz<\/option><option data-filter=\".uabb-masonary-cat-146\">Leitlinien<\/option><option data-filter=\".uabb-masonary-cat-147\">Palbociclib<\/option><\/select>\n\t\t\t\t\t\t<h3>\n\t\t\t\t<a href=\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/cyclin-dependent-kinase-4-6-inhibitors-for-treatment-of-hormone-receptor-positive-erbb2-negative-breast-cancer\/\" title=\"Cyclin-Dependent Kinase 4\/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer\" tabindex=\"0\">Cyclin-Dependent Kinase 4\/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer<\/a>\t\t\t<\/h3>\n\t\t\t<a href=\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/cyclin-dependent-kinase-4-6-inhibitors-for-treatment-of-hormone-receptor-positive-erbb2-negative-breast-cancer\/\" target=\"_blank\" rel=\"noopener\" role=\"button\" aria-label=\"WEITERLESEN\">\n\t\t\t\t\t\t\tWEITERLESEN\n\t\t<\/a>\n\t\t\t\t\t\t<h3>\n\t\t\t\t<a href=\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/ribociclib-and-endocrine-therapy-as-adjuvant-treatment-in-patients-with-hr-her2-early-breast-cancer-primary-results-from-the-phase-iii-natalee-trial\/\" title=\"Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+\/HER2- early breast cancer: Primary results from the phase III NATALEE trial\" tabindex=\"0\">Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+\/HER2- early breast cancer: Primary results from the phase III NATALEE trial<\/a>\t\t\t<\/h3>\n\t\t\t<a href=\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/ribociclib-and-endocrine-therapy-as-adjuvant-treatment-in-patients-with-hr-her2-early-breast-cancer-primary-results-from-the-phase-iii-natalee-trial\/\" target=\"_blank\" rel=\"noopener\" role=\"button\" aria-label=\"WEITERLESEN\">\n\t\t\t\t\t\t\tWEITERLESEN\n\t\t<\/a>\n\t\t\t\t\t\t<h3>\n\t\t\t\t<a href=\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/dalpiciclib-plus-letrozole-or-anastrozole-versus-placebo-plus-letrozole-or-anastrozole-as-first-line-treatment-in-patients-with-hormone-receptor-positive-her2-negative-advanced-breast-cancer-dawna-2\/\" title=\"Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial\" tabindex=\"0\">Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial<\/a>\t\t\t<\/h3>\n\t\t\t<a href=\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/dalpiciclib-plus-letrozole-or-anastrozole-versus-placebo-plus-letrozole-or-anastrozole-as-first-line-treatment-in-patients-with-hormone-receptor-positive-her2-negative-advanced-breast-cancer-dawna-2\/\" target=\"_blank\" rel=\"noopener\" role=\"button\" aria-label=\"WEITERLESEN\">\n\t\t\t\t\t\t\tWEITERLESEN\n\t\t<\/a>\n\t\t\t\t\t\t<h3>\n\t\t\t\t<a href=\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/abemaciclib-plus-endocrine-therapy-for-hormone-receptor-positive-her2-negative-node-positive-high-risk-early-breast-cancer-monarche-results-from-a-preplanned-interim-analysis-of-a-randomised-op\/\" title=\"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial\" tabindex=\"0\">Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial<\/a>\t\t\t<\/h3>\n\t\t\t<a href=\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/abemaciclib-plus-endocrine-therapy-for-hormone-receptor-positive-her2-negative-node-positive-high-risk-early-breast-cancer-monarche-results-from-a-preplanned-interim-analysis-of-a-randomised-op\/\" target=\"_blank\" rel=\"noopener\" role=\"button\" aria-label=\"WEITERLESEN\">\n\t\t\t\t\t\t\tWEITERLESEN\n\t\t<\/a>\n\t\t\t\t\t\t<h3>\n\t\t\t\t<a href=\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/a-look-at-current-and-potential-treatment-approaches-for-hormone-receptor-positive-her2-negative-early-breast-cancer\/\" title=\"A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer\" tabindex=\"0\">A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer<\/a>\t\t\t<\/h3>\n\t\t\t<a href=\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/a-look-at-current-and-potential-treatment-approaches-for-hormone-receptor-positive-her2-negative-early-breast-cancer\/\" target=\"_blank\" rel=\"noopener\" role=\"button\" aria-label=\"WEITERLESEN\">\n\t\t\t\t\t\t\tWEITERLESEN\n\t\t<\/a>\n\t\t\t\t\t\t<h3>\n\t\t\t\t<a href=\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/adjuvant-palbociclib-for-early-breast-cancer-the-pallas-trial-results-abcsg-42-aft-05-big-14-03\/\" title=\"Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42\/AFT-05\/BIG-14-03)\" tabindex=\"0\">Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42\/AFT-05\/BIG-14-03)<\/a>\t\t\t<\/h3>\n\t\t\t<a href=\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/adjuvant-palbociclib-for-early-breast-cancer-the-pallas-trial-results-abcsg-42-aft-05-big-14-03\/\" target=\"_blank\" rel=\"noopener\" role=\"button\" aria-label=\"WEITERLESEN\">\n\t\t\t\t\t\t\tWEITERLESEN\n\t\t<\/a>\n\t\t\t\t\t\t<h3>\n\t\t\t\t<a href=\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/cdk4-6-inhibition-in-early-stage-breast-cancer-how-far-is-it-from-becoming-standard-of-care\/\" title=\"CDK4\/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care?\" tabindex=\"0\">CDK4\/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care?<\/a>\t\t\t<\/h3>\n\t\t\t<a href=\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/cdk4-6-inhibition-in-early-stage-breast-cancer-how-far-is-it-from-becoming-standard-of-care\/\" target=\"_blank\" rel=\"noopener\" role=\"button\" aria-label=\"WEITERLESEN\">\n\t\t\t\t\t\t\tWEITERLESEN\n\t\t<\/a>\n\t\t\t\t\t\t<h3>\n\t\t\t\t<a href=\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/palbociclib-with-adjuvant-endocrine-therapy-in-early-breast-cancer-pallas-interim-analysis-of-a-multicentre-open-label-randomised-phase-3-study\/\" title=\"Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study\" tabindex=\"0\">Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study<\/a>\t\t\t<\/h3>\n\t\t\t<a href=\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/palbociclib-with-adjuvant-endocrine-therapy-in-early-breast-cancer-pallas-interim-analysis-of-a-multicentre-open-label-randomised-phase-3-study\/\" target=\"_blank\" rel=\"noopener\" role=\"button\" aria-label=\"WEITERLESEN\">\n\t\t\t\t\t\t\tWEITERLESEN\n\t\t<\/a>\n\t\t\t\t\t\t<h3>\n\t\t\t\t<a href=\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/early-breast-cancer-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up\/\" title=\"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\" tabindex=\"0\">Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<\/a>\t\t\t<\/h3>\n\t\t\t<a href=\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/early-breast-cancer-esmo-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up\/\" target=\"_blank\" rel=\"noopener\" role=\"button\" aria-label=\"WEITERLESEN\">\n\t\t\t\t\t\t\tWEITERLESEN\n\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t<a class=\"uabb-ss-grid-button-link\" href=\"https:\/\/www.xing.com\/app\/user?op=share&amp;url=https%3A%2F%2Fbreastcancer.knowledgehub.wiley.com%2Fde%2Fartikel%2F%3Ffl_builder\" target=\"_blank\" onclick=\"window.open(this.href,'social-share','left=20,top=20,width=500,height=500,toolbar=1,resizable=0');return false;\" rel=\"noopener\">\n\t\t\t\t\t\t\t\tXing\n\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t<a class=\"uabb-ss-grid-button-link\" href=\"https:\/\/www.facebook.com\/sharer.php?u=https%3A%2F%2Fbreastcancer.knowledgehub.wiley.com%2Fde%2Fartikel%2F%3Ffl_builder\" target=\"_blank\" onclick=\"window.open(this.href,'social-share','left=20,top=20,width=500,height=500,toolbar=1,resizable=0');return false;\" rel=\"noopener\">\n\t\t\t\t\t\t\t\tFacebook\n\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t<a class=\"uabb-ss-grid-button-link\" href=\"https:\/\/twitter.com\/share?url=https%3A%2F%2Fbreastcancer.knowledgehub.wiley.com%2Fde%2Fartikel%2F%3Ffl_builder\" target=\"_blank\" onclick=\"window.open(this.href,'social-share','left=20,top=20,width=500,height=500,toolbar=1,resizable=0');return false;\" rel=\"noopener\">\n\t\t\t\t\t\t\t\tTwitter\n\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t<a class=\"uabb-ss-grid-button-link\" href=\"https:\/\/www.linkedin.com\/shareArticle?url=https%3A%2F%2Fbreastcancer.knowledgehub.wiley.com%2Fde%2Fartikel%2F%3Ffl_builder\" target=\"_blank\" onclick=\"window.open(this.href,'social-share','left=20,top=20,width=500,height=500,toolbar=1,resizable=0');return false;\" rel=\"noopener\">\n\t\t\t\t\t\t\t\tLinkedin\n\t\t\t\t\t\t\t\t\t\t<\/a>\n","protected":false},"excerpt":{"rendered":"<p>Artikel &#8211; Brustkrebs Eine speziell zusammengestellte Liste von Artikeln mit Peer-Review, in denen die neuesten Fortschritte bei der Diagnose und Behandlung von Patientinnen mit Brustkrebs im Fr\u00fchstadium oder metastasiertem Brustkrebs behandelt werden. Filtern nach ThemaAbemaciclibAdjuvante TherapieAnastrozolBrustkrebs im Fr\u00fchstadiumCDK4\/6ChemotherapieDalpiciclibEndokrine TherapieKlinische StudienKonferenzLeitlinienPalbociclib Cyclin-Dependent Kinase 4\/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer WEITERLESEN Ribociclib and [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"page-builder","ast-site-content-layout":"full-width-container","site-content-style":"unboxed","site-sidebar-style":"unboxed","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-28313","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.1.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Artikel - Bildungsressourcen zum Thema Brustkrebs f\u00fcr medizinische Fachpersonen<\/title>\n<meta name=\"description\" content=\"Artikel mit Peer-Review zur Diagnose und Behandlung von Patientinnen mit Brustkrebs im Fr\u00fchstadium oder metastasiertem Brustkrebs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Artikel - Bildungsressourcen zum Thema Brustkrebs f\u00fcr medizinische Fachpersonen\" \/>\n<meta property=\"og:description\" content=\"Artikel mit Peer-Review zur Diagnose und Behandlung von Patientinnen mit Brustkrebs im Fr\u00fchstadium oder metastasiertem Brustkrebs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/\" \/>\n<meta property=\"og:site_name\" content=\"Bildungsressourcen zum Thema Brustkrebs f\u00fcr medizinische Fachpersonen\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-14T09:14:19+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/\",\"url\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/\",\"name\":\"Artikel - Bildungsressourcen zum Thema Brustkrebs f\u00fcr medizinische Fachpersonen\",\"isPartOf\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/#website\"},\"datePublished\":\"2021-11-04T14:30:12+00:00\",\"dateModified\":\"2024-03-14T09:14:19+00:00\",\"description\":\"Artikel mit Peer-Review zur Diagnose und Behandlung von Patientinnen mit Brustkrebs im Fr\u00fchstadium oder metastasiertem Brustkrebs.\",\"breadcrumb\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/#breadcrumb\"},\"inLanguage\":\"de-DE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Artikel\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/#website\",\"url\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/\",\"name\":\"Bildungsressourcen zum Thema Brustkrebs f\u00fcr medizinische Fachpersonen\",\"description\":\"Breast Cancer focused knowledge hub of resources, webinars, latest research and clinical updates for health care professionals who are treating patients living with Breast Cancer\",\"publisher\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de-DE\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/#organization\",\"name\":\"Wiley\",\"url\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de-DE\",\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/02\/Wiley_Logo.jpg\",\"contentUrl\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/02\/Wiley_Logo.jpg\",\"width\":696,\"height\":696,\"caption\":\"Wiley\"},\"image\":{\"@id\":\"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Artikel - Bildungsressourcen zum Thema Brustkrebs f\u00fcr medizinische Fachpersonen","description":"Artikel mit Peer-Review zur Diagnose und Behandlung von Patientinnen mit Brustkrebs im Fr\u00fchstadium oder metastasiertem Brustkrebs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/","og_locale":"de_DE","og_type":"article","og_title":"Artikel - Bildungsressourcen zum Thema Brustkrebs f\u00fcr medizinische Fachpersonen","og_description":"Artikel mit Peer-Review zur Diagnose und Behandlung von Patientinnen mit Brustkrebs im Fr\u00fchstadium oder metastasiertem Brustkrebs.","og_url":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/","og_site_name":"Bildungsressourcen zum Thema Brustkrebs f\u00fcr medizinische Fachpersonen","article_modified_time":"2024-03-14T09:14:19+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/","url":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/","name":"Artikel - Bildungsressourcen zum Thema Brustkrebs f\u00fcr medizinische Fachpersonen","isPartOf":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/#website"},"datePublished":"2021-11-04T14:30:12+00:00","dateModified":"2024-03-14T09:14:19+00:00","description":"Artikel mit Peer-Review zur Diagnose und Behandlung von Patientinnen mit Brustkrebs im Fr\u00fchstadium oder metastasiertem Brustkrebs.","breadcrumb":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/#breadcrumb"},"inLanguage":"de-DE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/artikel\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/"},{"@type":"ListItem","position":2,"name":"Artikel"}]},{"@type":"WebSite","@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/#website","url":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/","name":"Bildungsressourcen zum Thema Brustkrebs f\u00fcr medizinische Fachpersonen","description":"Breast Cancer focused knowledge hub of resources, webinars, latest research and clinical updates for health care professionals who are treating patients living with Breast Cancer","publisher":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de-DE"},{"@type":"Organization","@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/#organization","name":"Wiley","url":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/","logo":{"@type":"ImageObject","inLanguage":"de-DE","@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/#\/schema\/logo\/image\/","url":"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/02\/Wiley_Logo.jpg","contentUrl":"https:\/\/breastcancer.knowledgehub.wiley.com\/wp-content\/uploads\/2023\/02\/Wiley_Logo.jpg","width":696,"height":696,"caption":"Wiley"},"image":{"@id":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/wp-json\/wp\/v2\/pages\/28313","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/wp-json\/wp\/v2\/comments?post=28313"}],"version-history":[{"count":6,"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/wp-json\/wp\/v2\/pages\/28313\/revisions"}],"predecessor-version":[{"id":29341,"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/wp-json\/wp\/v2\/pages\/28313\/revisions\/29341"}],"wp:attachment":[{"href":"https:\/\/breastcancer.knowledgehub.wiley.com\/de\/wp-json\/wp\/v2\/media?parent=28313"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}